For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | - | 0 | - | - |
| Research and development | 27,376,912 | 23,132,671 | 20,359,098 | 22,047,254 |
| General and administrative | 9,395,941 | 6,023,337 | 5,924,942 | 5,671,880 |
| Total operating expenses | 36,772,853 | 29,156,008 | 26,284,040 | 27,719,134 |
| Loss from operations | -36,772,853 | -29,156,008 | -26,284,040 | -27,719,134 |
| Other income | 8,145 | 11,205 | 6,740 | 14,991 |
| Investment income | 2,904,506 | 2,021,214 | 1,713,499 | 1,793,352 |
| Interest expense | - | 3,124,484.5* | - | - |
| Gain on disposal of fixed assets | -81,143 | 78,759.5* | -6,846 | - |
| Total other income (expense) | 2,831,508 | -1,013,306 | 1,713,393 | 1,808,343 |
| Loss before income taxes | -33,941,345 | -30,170,514* | - | - |
| (provision for) benefit from income taxes | - | 400* | - | - |
| Net loss | -33,941,345 | -30,170,914 | -24,570,647 | -25,910,791 |
| Net unrealized gain (loss) on marketable securities | -536,881 | -560,968 | -543,452 | -424,353 |
| Comprehensive loss | -34,478,226 | -30,731,882 | -25,114,099 | -26,335,144 |
| Basic EPS | -0.59 | -0.629 | -0.54 | -0.57 |
| Diluted EPS | -0.59 | -0.629 | -0.54 | -0.57 |
| Basic Average Shares | 57,434,267 | 48,851,809 | 45,716,151 | 45,709,071 |
| Diluted Average Shares | 57,434,267 | 48,851,809 | 45,716,151 | 45,709,071 |
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)